Indonesian Political, Business & Finance News

BPOM: 87.5 per cent of marketing authorisations to be completed faster by 2026

| Source: Antara (Indonesian) Translated from Indonesian | Regulation
BPOM: 87.5 per cent of marketing authorisations to be completed faster by 2026
Image: Antara (Indonesian)

The Indonesian Food and Drug Authority (BPOM) has stated that 87.5 per cent of marketing authorisation issuances can be completed faster than the established timeline by 2026. This reflects the results of business process transformations aimed at maintaining a balance between the speed of innovation and public safety.

Speaking in Jakarta on Friday, the Head of BPOM, Taruna Ikrar, noted that this figure represents an increase from 70.6 per cent in 2024. He assessed that this transformation accelerates public access to medicines, vaccines, and innovative health products without compromising safety, efficacy, or quality.

“BPOM has translated the principle of regulatory innovation into a business process transformation, maintaining a balance between innovation speed and public safety. The intensity of supervision and regulatory processes is adjusted according to the risk level of each product,” said Taruna.

According to him, the acceleration of regulatory services is conducted through a risk-based approach. This approach is applied from the evaluation of marketing authorisations, pharmacovigilance, sampling and laboratory testing, inspections, to the implementation of clinical trials.

Furthermore, BPOM’s status as a WHO-Listed Authority (WLA) strengthens Indonesia’s position within the global regulatory system. Through the reliance mechanism, BPOM can utilise the assessment results of established regulators as a reference, while still conducting its own assessment process; this mechanism does not constitute direct recognition.

To accelerate public access, BPOM provides several registration pathways with different completion targets. For instance, Emergency Use Authorisation has a target completion time of 20 working days, while the pathway for new drug development and investment in Indonesia is targeted for completion within 50 working days.

“The reliance mechanism has a target completion of 90 working days, whereas the priority pathway is targeted for completion within 100 working days,” he added.

“BPOM is also developing several mechanisms to expand access to innovative therapies, including multi-regional clinical trials (MRCT), expanded access, and the assessment of conditional approval schemes for advanced therapy medicinal products (ATMP),” he said.

Taruna emphasised that the speed of access and public protection do not need to be in conflict. These various schemes are designed so that health innovations can be accessed more quickly by patients while maintaining safety and quality standards.

The acceleration of access to medicines and health innovation is also supported through collaboration with academia and the business sector. Currently, there are 186 universities serving as BPOM partners, alongside 277 pharmaceutical production facilities in Indonesia.

More from 11 September 2026 →

Cite this article
Source: jawawa.id (https://jawawa.id/newsitem/bpom-87-5-per-cent-of-marketing-authorisations-to-be-completed-faster-by-2026-1789142495)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5737196/bpom-875-persen-izin-edar-selesai-lebih-cepat-pada-2026), translated from Indonesian
Print